Previous 10 | Next 10 |
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
Clinical-stage biopharma company, Reata Pharmaceuticals (NASDAQ:RETA) ended a three-day losing streak on Tuesday after Goldman Sachs raised its price target to a Street high of $93 following the Texas-based firm’s 1Q 2022 results. Despite the mixed quarterly performance, the analysts l...
Reata Pharmaceuticals press release (NASDAQ:RETA): Q1 Non-GAAP EPS of -$1.33 beats by $0.63. Revenue of $0.91M (-3.2% Y/Y) misses by $0.64M. On March 31, 2022, we had cash and cash equivalents of $532.0 million, as compared to $590.3 million on December 31, 2021. The Company reaffirms its exi...
Completed Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreich’s Ataxia; Actively Preparing for Commercial Launch Updates Outcome of Type A Meeting with the FDA on the Protocol Amendment for FALCON Reaffirms Cash Runway Through e...
Reata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$1.96 (-5.4% Y/Y) and the consensus Revenue Estimate is $1.55M (+64.9% Y/Y). Over the last 2 years, RETA has beaten EPS estimates 63% of th...
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter en...
If Approved, Omaveloxolone Would Become the First Therapy Indicated for the Treatment of Patients with Friedreich’s Ataxia Friedreich’s Ataxia Affects Approximately 5,000 Patients in the United States with an Estimated 4,000 Diagnosed Patients ...
Reata's lead asset, bardoxolone, is beyond salvage. Omaveloxolone, the second asset, may be producing hope in some investors. However, I would be very careful about what Reata tells us about what the FDA told Reata. For further details see: Reata Pharmaceuticals: Once Be...
Citi detailed why the selloff of Reata Pharmaceuticals (NASDAQ:RETA -17.0%) was overdone after the clinical-stage biopharma company fell on Monday in reaction to negative views cited by the FDA on amyotrophic lateral sclerosis therapy, AMX0035. Developed by Amylyx Pharmaceuticals (A...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...